ArticleJournal of thrombosis and thrombolysis2026
Thrombotic and ischemic event reporting with anticoagulant reversal agents: a multi-agent FAERS pharmacovigilance study.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticoagulant reversal is usually performed during severe bleeding in patients who may remain at substantial thrombotic risk. We evaluated thrombotic and ischemic adverse-event reporting for andexanet alfa, idarucizumab, and a prothrombin complex concentrate (PCC) exposure set in the FDA Adverse Event Reporting System (FAERS). Public quarterly FAERS ASCII files from 2018Q2 through 2026Q1 were analyzed according to reporting principles for disproportionality analyses. Reports were deduplicated at case level. The primary exposure definition was primary or secondary suspect (PS/SS) reversal-agent reporting; all-role exposure, core-endpoint, and product/formulation-specific PCC analyses were sensitivity analyses. Exact Medical Dictionary for Regulatory Activities (MedDRA) preferred-term dictionaries defined thrombotic and ischemic endpoints. Reporting odds ratios (RORs), proportional reporting ratios (PRRs), and information component lower bounds (IC025) were calculated. The dataset included 11,586,364 deduplicated reports. PS/SS exposure sets included 1,086 andexanet alfa, 1,163 idarucizumab, and 1,080 PCC reports. The thrombotic/ischemic composite was reported in 371 andexanet reports (ROR 32.72, 95% CI 28.87-37.10), 156 idarucizumab reports (ROR 9.78, 95% CI 8.26-11.57), and 231 PCC reports (ROR 17.16, 95% CI 14.84-19.85). Ischemic stroke was the strongest andexanet component signal (ROR 120.38, 95% CI 103.88-139.49). FAERS reports showed disproportionate thrombotic and ischemic reporting for all three reversal-agent exposure sets, with a prominent andexanet signal for ischemic stroke. These findings are hypothesis-generating and should not be interpreted as incidence, causality, or a direct comparative clinical-risk estimate.
Indexed as
Identifiers
42749984What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.